Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

BACKGROUND: First-line nivolumab plus ipilimumab prolongs survival versus chemotherapy in advanced non-small-cell lung cancer (NSCLC). We further characterized clinical benefit with this regimen in a large pooled patient population and assessed the effect of response on survival. PATIENTS AND METHODS: Data were pooled from four studies of first-line nivolumab plus ipilimumab in advanced NSCLC (CheckMate 227 Part 1, 817 cohort A, 568 Part 1, and 012). Overall survival (OS), progression-free survival (PFS), objective response rate, duration of response, and safety were assessed. Landmark analyses of OS by response status at 6 months and by tumor burden reduction in responders to nivolumab plus ipilimumab were also assessed. RESULTS: In the pooled population (N = 1332) with a minimum follow-up of 29.1-58.9 months, median OS was 18.6 months, with a 3-year OS rate of 35%; median PFS was 5.4 months (3-year PFS rate, 17%). Objective response rate was 36%; median duration of response was 23.7 months, with 38% of responders having an ongoing response at 3 years. In patients with tumor programmed death-ligand 1 (PD-L1) <1%,

• Borghaei, H.
• Ciuleanu, T. E.
• Lee, J. S.
• Pluzanski, A.
• Caro, R. B.
• Gutierrez, M.
• Ohe, Y.
• Nishio, M.
• Goldman, J.
• Ready, N.
• Spigel, D. R.
• Ramalingam, S. S.
• Paz-Ares, L. G.
• Gainor, J. F.
• Ahmed, S.
• Reck, M.
• Maio, M.
• O'Byrne, K. J.
• Memaj, A.
• Nathan, F.
• Tran, P.
• Hellmann, M. D.
• Brahmer, J. R.